Fig. 1 · Structure

Documents & Downloads

Neostigmine bromide (Prostigmin)

Cat. No. A10635 CAS 114-80-7

AChE inhibitor

Neostigmine bromide is a reversible acetylcholine esterase inhibitor that binds to the anionic binding site of AChE.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AChR

Neostigmine bromide (Prostigmin) Research Summary

This section summarizes 4 in vitro studies of Neostigmine bromide (Prostigmin) from 3 published references. In vitro models include Echinoderma asperum; acetylcholinesterase (AChE) from Electrophorus electricus.

Neostigmine bromide (Prostigmin) In Vitro Studies

Neostigmine bromide produced very little inhibition of hydrolysing activity with ACh in Echinoderma asperum and no inhibition in Clitocybe phaeophthalma. Against acetylcholinesterase from Electrophorus electricus, the reported IC50 was 0.06 ± 0.01 mg/mL. In rat brain homogenate, FRC and FRH extracts showed significantly lower inhibitory activities than Neostigmine bromide, which served as the standard acetylcholinesterase inhibitor. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Limited inhibition of hydrolysing activity in Echinoderma asperum

Cell-based study · Echinoderma asperum [1]

In Echinoderma asperum, Neostigmine bromide at 1 mM produced very little inhibition of hydrolysing activity with ACh, reaching up to 20–30%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hydrolysing activity with AChACh hydrolysing activity up to 20–30%[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
a 15-min endogenous reaction; 25°C for 15 min
Method
10 μL of inhibitor
Vehicle
dH2O
Methods and source locations

Compound reported in the paper: Neostigmine bromide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Inhibition of ChE-like activities (S43, S44, S45, S46, S47, S48); Results > Influence of different inhibitors on ChE-like activity in mushroom aqueous extracts (S86); Fig 4 legend (S120)

hydrolysing activity with ACh: hydrolysing activity with ACh; comparator: buffer (100 mM, pH 7.4) instead of inhibitor — Results > Influence of different inhibitors on ChE-like activity in mushroom aqueous extracts (S86)

Acetylcholinesterase inhibition in Electrophorus electricus

Cell-based study · Acetylcholinesterase (AChE) from Electrophorus electricus [2]

Neostigmine bromide was mixed and incubated with acetylcholinesterase from Electrophorus electricus. The reported half-maximal inhibitory concentration was 0.06 ± 0.01 mg/mL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percent inhibition of acetylcholinesterase enzymeIC50 0.06 ± 0.01 mg/mL[2]

Literature-Reported Treatment Conditions

Exposure duration
15 min at 25 °C
Method
mixed and incubated
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Neostigmine bromide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

3. Materials and Methods > 3.1. Materials > 3.1.2. Chemicals (S4); 3. Materials and Methods > 3.8. Anti-Enzymatic Activities > 3.8.1. Acetylcholinesterase (AChE) Inhibition Assay (S85, S86, S87, S89, S90, S91); Table 4 (T4.h1, T4.r11)

percent inhibition of acetylcholinesterase enzyme: percent inhibition of acetylcholinesterase enzyme; comparator: the assay using the buffer instead of inhibitor (sample) — 3. Materials and Methods > 3.8. Anti-Enzymatic Activities > 3.8.1. Acetylcholinesterase (AChE) Inhibition Assay (S89); Table 4 (T4.h1, T4.r11)

Neostigmine comparator in rat brain homogenate

Cell-based study · rat brain homogenate [3]

Neostigmine bromide was used as positive control. Both the extracts (FRC and FRH): their inhibitory activities were significantly lower (P ≤ 0.001) than that of neostigmine bromide, a standard acetylcholinesterase inhibitor.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage Inhibition of cholinesterase activityReported result Both the extracts (FRC and FRH): their inhibitory activities were significantly lower (P ≤ 0.001) than that of neostigmine bromide, a standard acetylcholinesterase inhibitor.[3]

Literature-Reported Treatment Conditions

Exposure duration
incubated for 5 min at 25°C
Vehicle
0.1 mM sodium phosphate buffer (pH 8.0)
Reported limits
Not stated in the sentences used: dose, route.
Methods and source locations

Compound reported in the paper: Neostigmine bromide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > In vitro acteylcholinesterase inhibition assay (S8); MATERIALS AND METHODS > Assay procedure (S11, S12, S14, S16, S17); RESULTS (S21, S22)

percentage Inhibition of cholinesterase activity: percentage Inhibition of cholinesterase activity; comparator: control reaction (containing all reagents except the test compound) — MATERIALS AND METHODS > Assay procedure (S14); RESULTS (S21, S22)

No inhibition of hydrolysing activity in Clitocybe phaeophthalma

Cell-based study · Clitocybe phaeophthalma [1]

In Clitocybe phaeophthalma, Neostigmine bromide at 1 mM showed no inhibition of hydrolysing activity with ACh.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hydrolysing activity with AChReported result no (IDs 15, 31, 32, 37)[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
a 15-min endogenous reaction; 25°C for 15 min
Method
10 μL of inhibitor
Vehicle
dH2O
Methods and source locations

Compound reported in the paper: Neostigmine bromide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Inhibition of ChE-like activities (S43, S44, S45, S46, S47, S48); Results > Influence of different inhibitors on ChE-like activity in mushroom aqueous extracts (S86); Fig 4 legend (S120)

hydrolysing activity with ACh: hydrolysing activity with ACh; comparator: buffer (100 mM, pH 7.4) instead of inhibitor — Results > Influence of different inhibitors on ChE-like activity in mushroom aqueous extracts (S86)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 114-80-7
Applications AChE inhibitor
Formula C12H19BrN2O2
Molecular Weight 303.2
Synonyms Vagostigmin; Prostigmin
SMILES
CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 59 mg/mL (194.58 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Neostigmine bromide (Prostigmin) Research References

  1. [1] Sepčić K, Sabotič J, A Ohm R, et al. First evidence of cholinesterase-like activity in Basidiomycota. PLoS One (2019). PMID: 31039204 DOI: 10.1371/journal.pone.0216077 Source material
  2. [2] Castejón N, Parailloux M, Izdebska A, et al. Valorization of the Red Algae Gelidium sesquipedale by Extracting a Broad Spectrum of Minor Compounds Using Green Approaches. Mar Drugs (2021). PMID: 34677473 DOI: 10.3390/md19100574 Source material
  3. [3] Ahmed F, Urooj A. Anticholinesterase activities of cold and hot aqueous extracts of F. racemosa stem bark. Pharmacogn Mag (2010). PMID: 20668582 DOI: 10.4103/0973-1296.62897 Source material

Added to your cart

View Cart Checkout
Loading...